LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.12 -1.75

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.11

Max

1.15

Schlüsselkennzahlen
By Trading Economics
Einkommen	17M -26M
Angestellte	171
EBITDA	19M -23M

Dividenden
By Dow Jones
Nächstes Ergebnis	26. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-31M 72M
Vorheriger Eröffnungskurs	2.87
Vorheriger Schlusskurs	1.12

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Feb. 2026, 23:57 UTC

Heiße Aktien

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12. Feb. 2026, 23:35 UTC

Ergebnisse

Wichtige Markttreiber

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12. Feb. 2026, 23:28 UTC

Ergebnisse

Applied Materials Profit Rises on Soaring AI Demand -- Update

12. Feb. 2026, 21:47 UTC

Ergebnisse

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13. Feb. 2026, 00:00 UTC

Market Talk

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12. Feb. 2026, 23:47 UTC

Market Talk

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12. Feb. 2026, 23:38 UTC

Market Talk

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12. Feb. 2026, 23:33 UTC

Ergebnisse

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12. Feb. 2026, 23:09 UTC

Market Talk

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12. Feb. 2026, 22:55 UTC

Ergebnisse

Heiße Aktien

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12. Feb. 2026, 22:46 UTC

Market Talk

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12. Feb. 2026, 22:23 UTC

Ergebnisse

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12. Feb. 2026, 22:15 UTC

Ergebnisse

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12. Feb. 2026, 22:15 UTC

Ergebnisse

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12. Feb. 2026, 22:15 UTC

Ergebnisse

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12. Feb. 2026, 22:15 UTC

Ergebnisse

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12. Feb. 2026, 22:00 UTC

Ergebnisse

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12. Feb. 2026, 22:00 UTC

Ergebnisse

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12. Feb. 2026, 22:00 UTC

Ergebnisse

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12. Feb. 2026, 22:00 UTC

Ergebnisse

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12. Feb. 2026, 22:00 UTC

Ergebnisse

12. Feb. 2026, 22:00 UTC

Ergebnisse

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12. Feb. 2026, 21:57 UTC

Ergebnisse

XP 4Q Rev BRL4.95B >XP

12. Feb. 2026, 21:52 UTC

Ergebnisse

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12. Feb. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

12. Feb. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Feb. 2026, 21:47 UTC

Ergebnisse

Morningstar 4Q Rev $641M >MORN

12. Feb. 2026, 21:39 UTC

Ergebnisse

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12. Feb. 2026, 21:38 UTC

Ergebnisse

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Rating-Konsens

By TipRanks

Sell

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.